Medtronic PLC (NYSE:MDT) stock fell 0.89% (As on February 21, 11:40:17 AM UTC-4, Source: Google Finance) after the company raised annual profit forecast for the third time this fiscal year, after beating third-quarter expectations, helped by higher demand for its heart and diabetes devices. Demand for medical devices has picked up pace as non-urgent procedures, which were deferred during the pandemic, recovered in the past year with easing hospital staff shortages and people becoming regular with check-ups. The Cardiovascular Portfolio revenue was of $2.929 billion increased 6.1% as reported and 5.1% organic, with a low-double digit organic increase in SHA, mid-single digit organic increases in CPV, and low-single digit increase in CRHF. The Neuroscience Portfolio revenue was of $2.355 billion increased 4.8% as reported and 4.3% organic, with a mid-single digit organic increase in CST, low-single digit organic increases in Specialty Therapies and flat organic results in Neuromodulation. Diabetes revenue was of $640 million increased 12.3% as reported and 10.2% organic.
MDT in the third quarter of FY 23 has reported the adjusted earnings per share of $1.30, beating the analysts’ estimates for the adjusted earnings per share by 4 cents. The company had reported the adjusted revenue growth of 4.7 percent to $8.09 billion in the third quarter of FY 23, beating the analysts’ estimates for revenue of $7.95 billion, according to LSEG estimates. Q3 worldwide revenue grew 4.6% on an organic basis. The company’s organic revenue results reflect continued momentum across the company, driven by strong growth in Diabetes, Core Spine, Cardiac Surgery, Structural Heart, and Cardiac Pacing, as well as strength in international markets.
Meanwhile, the company has decided to exit its unprofitable ventilator product line within its patient monitoring and respiratory interventions (PMRI) business. It would retain and combine the remaining businesses within the PMRI operating units into a single unit called acute care and monitoring. In November the company was working on the separation of its PMRI business — a part of its medical surgical portfolio.
Medtronic expects an adjusted charge of between $350 million and $425 million in the fourth quarter related to the restructuring.
The company said these operational changes would eliminate the position of executive vice president and president of medical surgical portfolio, currently held by Robert White, who would leave effective April 26.
It expects adjusted profit for fiscal 2024 to be between $5.19 and $5.21 per share, compared with its previous range of $5.13 and $5.19 per share.